Trial Profile

A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (Dara-VCD) Induction Followed by Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients With Newly Diagnosed AL Amyloidosis

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 14 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bortezomib (Primary) ; Cyclophosphamide (Primary) ; Cyclophosphamide (Primary) ; Daratumumab/hyaluronidase (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary) ; Melphalan (Primary)
Indications Amyloid light-chain amyloidosis
Focus Therapeutic Use

07 Dec 2024 Study design discussed in an abstract published at 66th American Society of Hematology Annual Meeting and Exposition
08 Jul 2024 Status changed from not yet recruiting to recruiting.
10 Jun 2024 Planned initiation date changed from 1 May 2024 to 1 Jul 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com